Underprescription of Step III Opioids in French Cancer Survivors With Chronic Pain: A Call for Integrated Early Palliative Care in Oncology

• Published in: Journal of pain and symptom management Vol. 59; no. 4; pp. 836 - 847
• Main Authors: Janah, Asmaa, Bouhnik, Anne-Déborah, Touzani, Rajae, Bendiane, Marc-Karim, Peretti-Watel, Patrick
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2020; Elsevier Limited; Elsevier
• Subjects: Access; Bacteriology; Cancer; Cardiology and cardiovascular system; Chronic pain; Emerging diseases; health insurance data; Health status; Human health and pathology; Infectious diseases; Inpatient care; inpatient palliative care; Life Sciences; Medical diagnosis; Medical personnel; Microbiology and Parasitology; Narcotics; Oncology; Opioids; Pain; Palliative care; Parasitology; Prescribing; Prescription drugs; Risk factors; Survivor; Symptom management; Virology; cancer; health insurance data; inpatient palliative care; Chronic pain; opioids
• ISSN: 0885-3924; 1873-6513; 1873-6513
• DOI: 10.1016/j.jpainsymman.2019.10.027

Chronic pain (CP) is a major concern in cancer survivors. Often under-reported by patients, it is both underassessed and undertreated by care providers. To assess CP prevalence and related treatment in cancer survivors five years after diagnosis and to identify factors associated with prescribing opioids among survivors with CP, focusing on access to palliative care (PC). In 2015–2016, we interviewed 4174 French patients diagnosed with cancer five years previously. Combining patient-reported and clinical-reported outcomes together with medicoadministrative data, we studied factors associated with Step II and Step III opioid prescriptions in cancer survivors with CP. We performed multinomial logistic regression adjusting for various covariates, including self-reported health status variables and inpatient PC. Five years after cancer diagnosis, 63.5% of the respondents reported current CP (i.e., pain lasting three months or more). Of these, 64.6% and 14.4% were prescribed at least one Step II or Step III opioid, respectively. Only 1.9% had had inpatient PC since diagnosis. After adjustment for age, gender, clinical and self-reported variables, we found that the latter were more likely to receive Step III opioids (adjusted relative risk ratio 5.33; 95% CI 1.15, 24.58). This study showed a high prevalence of CP five years after cancer diagnosis. Step III opioids were underprescribed but positively associated with inpatient PC. PC access in France remains limited, especially among cancer survivors. Integrating PC in oncology is essential to provide the best cancer-related symptoms management.